A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

Part of paid clinical trials in Miami Lakes, Florida.

Sponsor
Incyte Corporation
Study ID
NCT07559396
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Renal Impairment

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • INCB123667 — DRUG
    Group 1: Single dose administered orally. Group 2: Two single doses administered orally.

Study Details

This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with severe renal impairment or end stage renal disease.

Key Dates

First listed
Apr 30, 2026
Start date
May 29, 2026
Status verified
Jun 2026
Primary completion
Jan 4, 2027
Completion
Jan 4, 2027

Study Design

Enrollment
16 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group 1: Severe Renal Impairment
    Participants with severe renal impairment will be enrolled in Group 1.
  • Experimental: Group 2: End Stage Renal Disease
    Participants with end stage renal disease will be enrolled in Group 2.

Primary Outcome Measure

PK for plasma INCB123667: Cmax [ Time Frame: Up to approximately 3 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Floridian Clinical ResearchMiami LakesFlorida33016-
Orlando Clinical Research CenterOrlandoFlorida32809-

Find similar trials in Miami Lakes, FL

By research site
Floridian Clinical Research· Miami Lakes, FLOrlando Clinical Research Center· Orlando, FL

Related Studies